PCP
INFI

Perimeter Capital Partners’s Infinity Pharmaceuticals, Inc. INFI Stock Holding History

Perimeter Capital Partners’s Portfolio INFI Stock Details INFI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-193,497
Closed -$3.37M – 231
2013
Q3 		$3.37M Buy
193,497
+33,582
+21% +$643K 0.63% 60
2013
Q2 		$2.59M Buy
+159,915
New +$4.95M 0.5% 103

Other funds holding INFI

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SCA
SAC Capital Advisors Stamford, Connecticut $19.3B AUM 31.93% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Perimeter Capital Partners's INFI Position: Q4 2013 in Review

Perimeter Capital Partners sold out of Infinity Pharmaceuticals, Inc. (INFI) in Q4 2013, closing a stake of 193,497 shares — an estimated $3.37M sold.

Perimeter Capital Partners first reported a position in INFI in Q2 2013 and held it in 2 quarters. The position peaked at $3.37M in Q3 2013. 104 funds tracked by Wall St. Rank hold INFI as of Q4 2013.

  • Perimeter Capital Partners reported no remaining Infinity Pharmaceuticals, Inc. position as of Q4 2013 after selling out during the quarter.
  • Perimeter Capital Partners sold 193,497 Infinity Pharmaceuticals, Inc. shares in Q4 2013, an estimated $3.37M.
  • Perimeter Capital Partners first reported a position in Infinity Pharmaceuticals, Inc. in Q2 2013 and held it in 2 quarters.
  • Perimeter Capital Partners's Infinity Pharmaceuticals, Inc. position peaked at $3.37M in Q3 2013.
  • 104 funds tracked by Wall St. Rank held Infinity Pharmaceuticals, Inc. as of Q4 2013.

Based on Perimeter Capital Partners's 13F filing for Q4 2013, filed 10 Feb 2014.